Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180760 | 0.84 | NPC1 (0.47) | HPGDKMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL6808909 | 0.79 | SMN1; SMN2 (0.38) | MAPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL14863636 | 0.78 | L3MBTL1 (0.46) | KMT2AMEN1KDM4EALDH1A1HDAC6 | |
| SCHEMBL14863635 | 0.78 | L3MBTL1 (0.46) | KMT2AMEN1KDM4EALDH1A1HDAC6 | |
| SCHEMBL14873381 | 0.72 | KCNA5 (0.42) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL6254877 | 0.71 | MME (0.46) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6993237 | 0.71 | MME (0.46) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL20217274 | 0.70 | KCNA5 (0.41) | MAPTKMT2AMEN1GAAKDM4E | |
| SCHEMBL6803422 | 0.69 | CTSS (0.52) | HPGD | |
| SCHEMBL6807801 | 0.69 | KCNA5 (0.39) | MAPTKMT2AMEN1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | MAPT 3461/4885HPGD 852/4885KMT2A 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.